| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 183 | 2022 | 1224 | 18.780 |
Why?
|
| Bronchodilator Agents | 28 | 2019 | 256 | 3.610 |
Why?
|
| Forced Expiratory Volume | 61 | 2022 | 545 | 3.370 |
Why?
|
| Smoking | 53 | 2022 | 1632 | 3.120 |
Why?
|
| Pulmonary Emphysema | 35 | 2021 | 315 | 3.060 |
Why?
|
| Spirometry | 33 | 2022 | 276 | 2.470 |
Why?
|
| Tomography, X-Ray Computed | 40 | 2022 | 2380 | 2.050 |
Why?
|
| Quality of Life | 49 | 2022 | 2136 | 1.980 |
Why?
|
| Lung | 37 | 2022 | 3637 | 1.910 |
Why?
|
| Emphysema | 12 | 2018 | 108 | 1.700 |
Why?
|
| Aged | 139 | 2022 | 20109 | 1.570 |
Why?
|
| Oxygen Inhalation Therapy | 15 | 2021 | 158 | 1.540 |
Why?
|
| Severity of Illness Index | 53 | 2022 | 2828 | 1.460 |
Why?
|
| Smokers | 9 | 2021 | 145 | 1.390 |
Why?
|
| Middle Aged | 144 | 2022 | 28753 | 1.380 |
Why?
|
| Respiratory Function Tests | 33 | 2020 | 595 | 1.280 |
Why?
|
| Genetic Predisposition to Disease | 27 | 2019 | 2424 | 1.220 |
Why?
|
| Exercise Tolerance | 16 | 2015 | 234 | 1.220 |
Why?
|
| Vital Capacity | 18 | 2021 | 254 | 1.200 |
Why?
|
| Humans | 228 | 2022 | 113846 | 1.150 |
Why?
|
| Disease Progression | 29 | 2022 | 2489 | 1.150 |
Why?
|
| Dyspnea | 15 | 2018 | 186 | 1.110 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 8 | 2017 | 41 | 1.100 |
Why?
|
| Albuterol | 5 | 2015 | 97 | 1.070 |
Why?
|
| Female | 159 | 2022 | 63035 | 1.040 |
Why?
|
| Male | 158 | 2022 | 60993 | 1.030 |
Why?
|
| Genome-Wide Association Study | 18 | 2019 | 1141 | 0.970 |
Why?
|
| Surveys and Questionnaires | 26 | 2022 | 4625 | 0.940 |
Why?
|
| Primary Health Care | 4 | 2018 | 1508 | 0.900 |
Why?
|
| Pneumonectomy | 13 | 2012 | 122 | 0.900 |
Why?
|
| Bronchitis, Chronic | 6 | 2019 | 25 | 0.890 |
Why?
|
| Managed Care Programs | 2 | 2012 | 156 | 0.840 |
Why?
|
| Comorbidity | 17 | 2022 | 1601 | 0.840 |
Why?
|
| Health Status Indicators | 5 | 2014 | 182 | 0.780 |
Why?
|
| Depression | 7 | 2019 | 1129 | 0.690 |
Why?
|
| Ipratropium | 2 | 2008 | 8 | 0.680 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2016 | 492 | 0.680 |
Why?
|
| Aged, 80 and over | 36 | 2022 | 6796 | 0.680 |
Why?
|
| Androstadienes | 2 | 2008 | 96 | 0.650 |
Why?
|
| Risk Factors | 39 | 2021 | 9050 | 0.640 |
Why?
|
| Health Status | 12 | 2015 | 773 | 0.630 |
Why?
|
| Hospitalization | 9 | 2020 | 1678 | 0.610 |
Why?
|
| Glucocorticoids | 7 | 2019 | 539 | 0.600 |
Why?
|
| Predictive Value of Tests | 16 | 2020 | 2025 | 0.590 |
Why?
|
| Treatment Outcome | 33 | 2019 | 9002 | 0.590 |
Why?
|
| Genetic Loci | 5 | 2019 | 277 | 0.580 |
Why?
|
| Follow-Up Studies | 23 | 2022 | 4906 | 0.560 |
Why?
|
| Anxiety | 5 | 2019 | 757 | 0.560 |
Why?
|
| Formoterol Fumarate | 5 | 2017 | 8 | 0.560 |
Why?
|
| Medicare | 3 | 2022 | 606 | 0.550 |
Why?
|
| Hypoxia | 6 | 2021 | 940 | 0.550 |
Why?
|
| Multivariate Analysis | 20 | 2019 | 1599 | 0.540 |
Why?
|
| Health Services Accessibility | 3 | 2021 | 777 | 0.540 |
Why?
|
| Case-Control Studies | 21 | 2020 | 3369 | 0.540 |
Why?
|
| Asthma | 7 | 2021 | 1933 | 0.530 |
Why?
|
| Lung Diseases, Obstructive | 6 | 2002 | 62 | 0.520 |
Why?
|
| Polymorphism, Single Nucleotide | 12 | 2019 | 2052 | 0.510 |
Why?
|
| Cross-Sectional Studies | 24 | 2022 | 4275 | 0.500 |
Why?
|
| Cognition | 5 | 2021 | 964 | 0.500 |
Why?
|
| Randomized Controlled Trials as Topic | 11 | 2017 | 1136 | 0.500 |
Why?
|
| Cohort Studies | 28 | 2020 | 5011 | 0.490 |
Why?
|
| Administration, Inhalation | 10 | 2016 | 649 | 0.470 |
Why?
|
| Respiration, Artificial | 5 | 2002 | 566 | 0.470 |
Why?
|
| Risk Assessment | 15 | 2020 | 3147 | 0.470 |
Why?
|
| Clinical Trials as Topic | 5 | 2010 | 1009 | 0.460 |
Why?
|
| United States | 34 | 2022 | 12329 | 0.460 |
Why?
|
| Cognitive Dysfunction | 3 | 2021 | 249 | 0.450 |
Why?
|
| Psychometrics | 5 | 2018 | 671 | 0.440 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 388 | 0.430 |
Why?
|
| Proportional Hazards Models | 11 | 2019 | 1141 | 0.430 |
Why?
|
| African Americans | 8 | 2018 | 1101 | 0.410 |
Why?
|
| Cigarette Smoking | 3 | 2021 | 73 | 0.410 |
Why?
|
| Patient Compliance | 4 | 2012 | 604 | 0.410 |
Why?
|
| Airway Obstruction | 4 | 2019 | 161 | 0.410 |
Why?
|
| Health Personnel | 1 | 2015 | 485 | 0.400 |
Why?
|
| Adaptation, Psychological | 2 | 2013 | 577 | 0.400 |
Why?
|
| Time Factors | 21 | 2020 | 7060 | 0.400 |
Why?
|
| Prospective Studies | 19 | 2021 | 6250 | 0.390 |
Why?
|
| Neuropsychological Tests | 6 | 2021 | 1095 | 0.380 |
Why?
|
| Logistic Models | 12 | 2021 | 2053 | 0.380 |
Why?
|
| Carbon Monoxide | 4 | 2021 | 72 | 0.370 |
Why?
|
| Curriculum | 1 | 2015 | 818 | 0.370 |
Why?
|
| Adult | 41 | 2022 | 31979 | 0.370 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 135 | 0.370 |
Why?
|
| Exercise | 7 | 2010 | 1718 | 0.370 |
Why?
|
| Drug Therapy, Combination | 6 | 2016 | 1004 | 0.360 |
Why?
|
| Phenotype | 15 | 2020 | 3050 | 0.350 |
Why?
|
| Sex Factors | 11 | 2021 | 1997 | 0.350 |
Why?
|
| Respiratory Mechanics | 4 | 2013 | 80 | 0.350 |
Why?
|
| Budesonide, Formoterol Fumarate Drug Combination | 2 | 2017 | 2 | 0.350 |
Why?
|
| Linear Models | 8 | 2018 | 909 | 0.340 |
Why?
|
| Budesonide | 3 | 2016 | 82 | 0.330 |
Why?
|
| Machine Learning | 2 | 2020 | 243 | 0.330 |
Why?
|
| Pulmonary Diffusing Capacity | 4 | 2019 | 59 | 0.320 |
Why?
|
| Physicians, Primary Care | 1 | 2010 | 246 | 0.310 |
Why?
|
| Biomedical Research | 4 | 2015 | 609 | 0.290 |
Why?
|
| Oxygen | 6 | 2021 | 892 | 0.290 |
Why?
|
| Ethanolamines | 2 | 2015 | 19 | 0.290 |
Why?
|
| Smoking Cessation | 6 | 2018 | 379 | 0.290 |
Why?
|
| Respiration Disorders | 2 | 2021 | 61 | 0.290 |
Why?
|
| Home Care Services | 4 | 2021 | 232 | 0.290 |
Why?
|
| Prognosis | 12 | 2021 | 3544 | 0.290 |
Why?
|
| Muscarinic Antagonists | 2 | 2015 | 27 | 0.280 |
Why?
|
| Exercise Test | 7 | 2015 | 598 | 0.280 |
Why?
|
| Double-Blind Method | 8 | 2018 | 1673 | 0.280 |
Why?
|
| Walking | 6 | 2015 | 383 | 0.280 |
Why?
|
| Practice Guidelines as Topic | 5 | 2015 | 1529 | 0.270 |
Why?
|
| Airway Remodeling | 3 | 2019 | 59 | 0.270 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 3 | 2016 | 379 | 0.260 |
Why?
|
| DNA Methylation | 2 | 2020 | 440 | 0.260 |
Why?
|
| Area Under Curve | 4 | 2015 | 328 | 0.260 |
Why?
|
| Longitudinal Studies | 11 | 2021 | 2692 | 0.260 |
Why?
|
| Retrospective Studies | 14 | 2022 | 11340 | 0.250 |
Why?
|
| Survival Analysis | 7 | 2019 | 1414 | 0.250 |
Why?
|
| Evidence-Based Medicine | 4 | 2015 | 728 | 0.250 |
Why?
|
| Cost of Illness | 3 | 2014 | 288 | 0.250 |
Why?
|
| Cognition Disorders | 1 | 2008 | 584 | 0.250 |
Why?
|
| Air Pollution | 1 | 2005 | 178 | 0.240 |
Why?
|
| Seasons | 1 | 2005 | 439 | 0.240 |
Why?
|
| Pectoralis Muscles | 2 | 2021 | 22 | 0.240 |
Why?
|
| Clinical Protocols | 2 | 2019 | 240 | 0.240 |
Why?
|
| Pulmonary Fibrosis | 3 | 2016 | 344 | 0.230 |
Why?
|
| Carotid Arteries | 2 | 2021 | 194 | 0.230 |
Why?
|
| Behavior | 1 | 2002 | 117 | 0.230 |
Why?
|
| Hypoventilation | 1 | 2021 | 9 | 0.230 |
Why?
|
| Patient Readmission | 1 | 2007 | 621 | 0.230 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2018 | 232 | 0.230 |
Why?
|
| Antidepressive Agents | 3 | 2019 | 197 | 0.230 |
Why?
|
| Polycythemia | 1 | 2021 | 30 | 0.230 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 2 | 2013 | 74 | 0.220 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2018 | 460 | 0.220 |
Why?
|
| Noninvasive Ventilation | 1 | 2021 | 31 | 0.220 |
Why?
|
| Sickness Impact Profile | 1 | 2001 | 64 | 0.220 |
Why?
|
| Muscular Atrophy | 1 | 2021 | 57 | 0.220 |
Why?
|
| Forecasting | 2 | 2022 | 399 | 0.210 |
Why?
|
| Societies, Medical | 2 | 2015 | 768 | 0.210 |
Why?
|
| Altitude | 1 | 2005 | 467 | 0.210 |
Why?
|
| Symptom Assessment | 2 | 2018 | 126 | 0.210 |
Why?
|
| Pulmonary Artery | 2 | 2020 | 1079 | 0.210 |
Why?
|
| Research Design | 4 | 2017 | 913 | 0.210 |
Why?
|
| Bronchioles | 1 | 2019 | 26 | 0.210 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2019 | 11 | 0.210 |
Why?
|
| Graft vs Host Disease | 1 | 2022 | 229 | 0.200 |
Why?
|
| Education | 2 | 2018 | 110 | 0.200 |
Why?
|
| Reproducibility of Results | 7 | 2018 | 2905 | 0.200 |
Why?
|
| Carotid Artery Diseases | 1 | 2020 | 64 | 0.200 |
Why?
|
| Drug Combinations | 2 | 2015 | 300 | 0.200 |
Why?
|
| Molecular Epidemiology | 1 | 2019 | 63 | 0.200 |
Why?
|
| Prevalence | 8 | 2021 | 2407 | 0.200 |
Why?
|
| Metoprolol | 1 | 2019 | 46 | 0.200 |
Why?
|
| Addison Disease | 1 | 2019 | 44 | 0.200 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2019 | 17 | 0.200 |
Why?
|
| Hyperostosis, Diffuse Idiopathic Skeletal | 1 | 2019 | 9 | 0.200 |
Why?
|
| Europe | 6 | 2019 | 351 | 0.200 |
Why?
|
| Genome, Human | 3 | 2019 | 394 | 0.200 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2019 | 28 | 0.190 |
Why?
|
| Neuromuscular Diseases | 3 | 2002 | 99 | 0.190 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2019 | 36 | 0.190 |
Why?
|
| Peak Expiratory Flow Rate | 4 | 2017 | 39 | 0.190 |
Why?
|
| Anti-Anxiety Agents | 1 | 2019 | 51 | 0.190 |
Why?
|
| Walk Test | 4 | 2021 | 52 | 0.190 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2014 | 388 | 0.190 |
Why?
|
| Interdisciplinary Studies | 1 | 2018 | 22 | 0.190 |
Why?
|
| Whole Exome Sequencing | 1 | 2018 | 88 | 0.190 |
Why?
|
| Mitogen-Activated Protein Kinase 14 | 1 | 2018 | 7 | 0.180 |
Why?
|
| Patient Outcome Assessment | 2 | 2021 | 124 | 0.180 |
Why?
|
| Health Facilities | 1 | 1998 | 53 | 0.180 |
Why?
|
| Genetic Association Studies | 3 | 2018 | 415 | 0.180 |
Why?
|
| Genetic Markers | 1 | 2019 | 402 | 0.180 |
Why?
|
| Age Factors | 7 | 2019 | 3330 | 0.180 |
Why?
|
| Body Mass Index | 7 | 2021 | 2098 | 0.170 |
Why?
|
| Hypnotics and Sedatives | 1 | 2019 | 137 | 0.170 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2021 | 220 | 0.170 |
Why?
|
| Translations | 1 | 2017 | 15 | 0.170 |
Why?
|
| Eicosanoids | 1 | 2017 | 65 | 0.170 |
Why?
|
| Pyrazines | 1 | 2018 | 86 | 0.170 |
Why?
|
| Circadian Rhythm | 3 | 2015 | 456 | 0.170 |
Why?
|
| Vaping | 1 | 2017 | 25 | 0.170 |
Why?
|
| Long-Term Care | 3 | 2013 | 74 | 0.170 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2013 | 1227 | 0.170 |
Why?
|
| Population Surveillance | 1 | 2021 | 439 | 0.170 |
Why?
|
| Benzamides | 1 | 2018 | 186 | 0.170 |
Why?
|
| Respiratory Tract Diseases | 2 | 2014 | 158 | 0.160 |
Why?
|
| Respiration | 2 | 1989 | 194 | 0.160 |
Why?
|
| Interleukin-27 | 1 | 2016 | 15 | 0.160 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2016 | 73 | 0.160 |
Why?
|
| Regression Analysis | 5 | 2019 | 1137 | 0.160 |
Why?
|
| Receptors, Nicotinic | 1 | 2019 | 335 | 0.160 |
Why?
|
| HLA-DRB1 Chains | 1 | 2016 | 104 | 0.150 |
Why?
|
| Attention | 1 | 2019 | 469 | 0.150 |
Why?
|
| Chromatography, Liquid | 1 | 2017 | 348 | 0.150 |
Why?
|
| Nebulizers and Vaporizers | 2 | 2013 | 87 | 0.150 |
Why?
|
| Memory | 2 | 2010 | 301 | 0.150 |
Why?
|
| Anti-Bacterial Agents | 2 | 2018 | 1331 | 0.150 |
Why?
|
| Pharmacogenomic Variants | 1 | 2015 | 42 | 0.150 |
Why?
|
| Sputum | 1 | 2017 | 286 | 0.150 |
Why?
|
| Vascular Stiffness | 1 | 2020 | 379 | 0.150 |
Why?
|
| Blood Cells | 1 | 2015 | 40 | 0.150 |
Why?
|
| Physical Endurance | 2 | 2010 | 263 | 0.150 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2017 | 398 | 0.150 |
Why?
|
| Exome | 1 | 2016 | 215 | 0.150 |
Why?
|
| Colorado | 6 | 2010 | 4581 | 0.150 |
Why?
|
| Bronchi | 2 | 2007 | 242 | 0.150 |
Why?
|
| Respiratory System | 1 | 2016 | 140 | 0.150 |
Why?
|
| Respiratory Insufficiency | 2 | 1998 | 279 | 0.150 |
Why?
|
| Multicenter Studies as Topic | 4 | 2012 | 222 | 0.140 |
Why?
|
| Disease Management | 3 | 2019 | 606 | 0.140 |
Why?
|
| Pneumothorax | 1 | 2014 | 35 | 0.140 |
Why?
|
| Spinal Fractures | 1 | 2015 | 58 | 0.140 |
Why?
|
| Klinefelter Syndrome | 1 | 2015 | 47 | 0.140 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2017 | 655 | 0.140 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2017 | 368 | 0.140 |
Why?
|
| Survival Rate | 6 | 2017 | 1854 | 0.130 |
Why?
|
| Tropanes | 1 | 2013 | 3 | 0.130 |
Why?
|
| Drug Administration Schedule | 3 | 2014 | 825 | 0.130 |
Why?
|
| Simvastatin | 1 | 2014 | 71 | 0.130 |
Why?
|
| Activities of Daily Living | 3 | 2021 | 369 | 0.130 |
Why?
|
| Factor Analysis, Statistical | 4 | 2018 | 291 | 0.130 |
Why?
|
| Bronchiectasis | 2 | 2008 | 97 | 0.130 |
Why?
|
| Physicians | 1 | 2021 | 711 | 0.130 |
Why?
|
| Lung Diseases | 2 | 2013 | 750 | 0.130 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 401 | 0.130 |
Why?
|
| Community Health Services | 1 | 2015 | 209 | 0.130 |
Why?
|
| Radiography, Thoracic | 4 | 2015 | 182 | 0.130 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 1045 | 0.130 |
Why?
|
| Reference Values | 3 | 2014 | 877 | 0.130 |
Why?
|
| ROC Curve | 1 | 2015 | 488 | 0.130 |
Why?
|
| Probability | 3 | 2009 | 341 | 0.130 |
Why?
|
| Costs and Cost Analysis | 3 | 2012 | 210 | 0.130 |
Why?
|
| Total Lung Capacity | 5 | 2011 | 44 | 0.130 |
Why?
|
| Data Interpretation, Statistical | 2 | 2005 | 344 | 0.130 |
Why?
|
| Osteoporosis | 1 | 2015 | 195 | 0.120 |
Why?
|
| Muscle Strength | 2 | 2018 | 245 | 0.120 |
Why?
|
| Thymus Neoplasms | 1 | 1992 | 21 | 0.120 |
Why?
|
| Thymoma | 1 | 1992 | 32 | 0.120 |
Why?
|
| Sensitivity and Specificity | 5 | 2018 | 1930 | 0.120 |
Why?
|
| Telecommunications | 1 | 2012 | 18 | 0.120 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2014 | 214 | 0.120 |
Why?
|
| Cross-Over Studies | 2 | 2018 | 484 | 0.120 |
Why?
|
| Agammaglobulinemia | 1 | 1992 | 36 | 0.120 |
Why?
|
| Rest | 4 | 2016 | 138 | 0.120 |
Why?
|
| Trail Making Test | 1 | 2011 | 5 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2011 | 32 | 0.120 |
Why?
|
| Physical Exertion | 3 | 2013 | 252 | 0.120 |
Why?
|
| Pulmonary Ventilation | 2 | 2009 | 83 | 0.120 |
Why?
|
| Lung Transplantation | 2 | 2011 | 307 | 0.120 |
Why?
|
| Bronchography | 1 | 2011 | 11 | 0.120 |
Why?
|
| Genetic Variation | 2 | 2014 | 991 | 0.120 |
Why?
|
| Health Care Costs | 3 | 2022 | 395 | 0.120 |
Why?
|
| Chronic Disease | 6 | 2010 | 1681 | 0.120 |
Why?
|
| Spiritualism | 1 | 2011 | 2 | 0.120 |
Why?
|
| Focus Groups | 1 | 2013 | 357 | 0.110 |
Why?
|
| Bone Density | 1 | 2015 | 401 | 0.110 |
Why?
|
| Fatigue Syndrome, Chronic | 2 | 2003 | 19 | 0.110 |
Why?
|
| Pneumococcal Infections | 1 | 2012 | 96 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 858 | 0.110 |
Why?
|
| Morbidity | 1 | 2012 | 259 | 0.110 |
Why?
|
| Telemedicine | 1 | 2018 | 540 | 0.110 |
Why?
|
| Heart | 1 | 2015 | 685 | 0.110 |
Why?
|
| Patient Preference | 1 | 2013 | 159 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2014 | 2229 | 0.110 |
Why?
|
| Insurance Claim Review | 1 | 2011 | 68 | 0.110 |
Why?
|
| Azithromycin | 1 | 2011 | 82 | 0.110 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2010 | 17 | 0.110 |
Why?
|
| Religion | 1 | 2011 | 71 | 0.110 |
Why?
|
| Interviews as Topic | 1 | 2013 | 629 | 0.110 |
Why?
|
| Pneumococcal Vaccines | 1 | 2012 | 134 | 0.110 |
Why?
|
| Sirtuin 2 | 1 | 2010 | 17 | 0.110 |
Why?
|
| Stress, Psychological | 2 | 2010 | 1127 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2010 | 36 | 0.110 |
Why?
|
| Cluster Analysis | 3 | 2019 | 490 | 0.110 |
Why?
|
| Epoxide Hydrolases | 2 | 2007 | 11 | 0.110 |
Why?
|
| Trachea | 2 | 2009 | 229 | 0.110 |
Why?
|
| Critical Care | 1 | 2015 | 519 | 0.110 |
Why?
|
| Radiography | 4 | 2014 | 828 | 0.100 |
Why?
|
| Family Conflict | 1 | 2010 | 43 | 0.100 |
Why?
|
| STAT1 Transcription Factor | 1 | 2010 | 79 | 0.100 |
Why?
|
| Social Support | 5 | 2010 | 544 | 0.100 |
Why?
|
| Intubation, Intratracheal | 1 | 1992 | 202 | 0.100 |
Why?
|
| Motor Activity | 2 | 2013 | 756 | 0.100 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2009 | 29 | 0.100 |
Why?
|
| Aorta | 1 | 2012 | 410 | 0.100 |
Why?
|
| Family Relations | 1 | 2009 | 81 | 0.100 |
Why?
|
| Exercise Therapy | 3 | 2013 | 363 | 0.100 |
Why?
|
| Patient Education as Topic | 5 | 2009 | 739 | 0.100 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2010 | 120 | 0.100 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2009 | 135 | 0.100 |
Why?
|
| Data Collection | 1 | 2012 | 672 | 0.100 |
Why?
|
| DNA Helicases | 1 | 2010 | 128 | 0.100 |
Why?
|
| Self Report | 1 | 2013 | 684 | 0.100 |
Why?
|
| Respiratory Tract Infections | 1 | 1992 | 267 | 0.090 |
Why?
|
| Salmeterol Xinafoate | 1 | 2008 | 35 | 0.090 |
Why?
|
| Bupropion | 1 | 2008 | 39 | 0.090 |
Why?
|
| Benzazepines | 1 | 2008 | 45 | 0.090 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2008 | 40 | 0.090 |
Why?
|
| Fluticasone | 1 | 2008 | 75 | 0.090 |
Why?
|
| Oxygen Consumption | 1 | 2011 | 664 | 0.090 |
Why?
|
| Quinoxalines | 1 | 2008 | 68 | 0.090 |
Why?
|
| Catheterization | 1 | 2009 | 181 | 0.090 |
Why?
|
| Maximum Tolerated Dose | 1 | 2008 | 187 | 0.090 |
Why?
|
| Ambulatory Care | 1 | 2012 | 461 | 0.090 |
Why?
|
| Smoking Prevention | 1 | 2008 | 164 | 0.090 |
Why?
|
| Respiratory Therapy | 1 | 2007 | 19 | 0.090 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2007 | 10 | 0.090 |
Why?
|
| Family Health | 1 | 2008 | 209 | 0.090 |
Why?
|
| Cause of Death | 2 | 2020 | 383 | 0.080 |
Why?
|
| Life Expectancy | 1 | 2007 | 64 | 0.080 |
Why?
|
| Cardiovascular Diseases | 2 | 2014 | 1711 | 0.080 |
Why?
|
| Norway | 3 | 2010 | 40 | 0.080 |
Why?
|
| Patient Dropouts | 2 | 2017 | 79 | 0.080 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2006 | 34 | 0.080 |
Why?
|
| Caregivers | 1 | 2013 | 643 | 0.080 |
Why?
|
| Linkage Disequilibrium | 3 | 2016 | 331 | 0.080 |
Why?
|
| Awareness | 1 | 2007 | 93 | 0.080 |
Why?
|
| Age of Onset | 3 | 2014 | 494 | 0.080 |
Why?
|
| Patient Discharge | 3 | 2021 | 743 | 0.080 |
Why?
|
| Acute Disease | 3 | 2014 | 1000 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 872 | 0.080 |
Why?
|
| Treatment Failure | 2 | 2019 | 329 | 0.080 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 969 | 0.080 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 775 | 0.080 |
Why?
|
| Genotype | 3 | 2018 | 2074 | 0.080 |
Why?
|
| Mothers | 1 | 2011 | 593 | 0.080 |
Why?
|
| Fluticasone-Salmeterol Drug Combination | 1 | 2005 | 12 | 0.080 |
Why?
|
| Ohio | 1 | 2005 | 128 | 0.080 |
Why?
|
| Oximetry | 2 | 2016 | 81 | 0.070 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2005 | 96 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 15 | 2 | 2015 | 85 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2010 | 528 | 0.070 |
Why?
|
| Patient Admission | 1 | 2007 | 198 | 0.070 |
Why?
|
| Nitrogen Dioxide | 1 | 2005 | 26 | 0.070 |
Why?
|
| Heart Rate | 2 | 2021 | 844 | 0.070 |
Why?
|
| Executive Function | 2 | 2020 | 374 | 0.070 |
Why?
|
| Self-Assessment | 2 | 2017 | 73 | 0.070 |
Why?
|
| Proteins | 1 | 2010 | 998 | 0.070 |
Why?
|
| Salvage Therapy | 1 | 2005 | 137 | 0.070 |
Why?
|
| Heart Failure | 1 | 2016 | 1899 | 0.070 |
Why?
|
| Algorithms | 1 | 2011 | 1558 | 0.070 |
Why?
|
| Dry Powder Inhalers | 2 | 2013 | 4 | 0.070 |
Why?
|
| Health Education | 1 | 2007 | 321 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 4 | 2 | 2015 | 36 | 0.070 |
Why?
|
| Epigenesis, Genetic | 2 | 2020 | 489 | 0.060 |
Why?
|
| Smoke | 1 | 2005 | 134 | 0.060 |
Why?
|
| Treatment Refusal | 1 | 2003 | 90 | 0.060 |
Why?
|
| Particle Size | 1 | 2005 | 409 | 0.060 |
Why?
|
| Gene Frequency | 2 | 2016 | 572 | 0.060 |
Why?
|
| Preoperative Care | 1 | 2005 | 339 | 0.060 |
Why?
|
| Body Composition | 2 | 2021 | 738 | 0.060 |
Why?
|
| Environmental Monitoring | 1 | 2005 | 297 | 0.060 |
Why?
|
| Palliative Care | 1 | 2009 | 631 | 0.060 |
Why?
|
| Incidence | 3 | 2015 | 2470 | 0.060 |
Why?
|
| North America | 2 | 2015 | 274 | 0.060 |
Why?
|
| Registries | 2 | 2021 | 1824 | 0.060 |
Why?
|
| Decision Making | 1 | 2008 | 774 | 0.060 |
Why?
|
| Cough | 2 | 2016 | 96 | 0.060 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 93 | 0.060 |
Why?
|
| Physician's Role | 1 | 2003 | 221 | 0.060 |
Why?
|
| Learning | 1 | 2005 | 373 | 0.060 |
Why?
|
| Patient Care Planning | 1 | 2002 | 166 | 0.060 |
Why?
|
| Carotid Artery, Common | 1 | 2021 | 28 | 0.060 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2021 | 70 | 0.050 |
Why?
|
| Self Care | 1 | 2003 | 360 | 0.050 |
Why?
|
| Polysomnography | 1 | 2021 | 183 | 0.050 |
Why?
|
| Pulmonary Medicine | 1 | 2021 | 86 | 0.050 |
Why?
|
| Gene Expression | 2 | 2019 | 1588 | 0.050 |
Why?
|
| Complement Activation | 1 | 2003 | 333 | 0.050 |
Why?
|
| Stroke Volume | 2 | 2015 | 522 | 0.050 |
Why?
|
| Biomarkers | 3 | 2017 | 3501 | 0.050 |
Why?
|
| Fever | 1 | 2022 | 316 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2022 | 306 | 0.050 |
Why?
|
| Adolescent | 5 | 2018 | 18736 | 0.050 |
Why?
|
| Hydrocortisone | 2 | 2019 | 322 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 2041 | 0.050 |
Why?
|
| Air | 1 | 2020 | 55 | 0.050 |
Why?
|
| Thyroid Diseases | 1 | 2019 | 38 | 0.050 |
Why?
|
| rab4 GTP-Binding Proteins | 1 | 2019 | 10 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2019 | 12 | 0.050 |
Why?
|
| Anthropometry | 1 | 2020 | 198 | 0.050 |
Why?
|
| Cytochrome P450 Family 2 | 1 | 2019 | 13 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2A6 | 1 | 2019 | 14 | 0.050 |
Why?
|
| Desmoplakins | 1 | 2019 | 24 | 0.050 |
Why?
|
| GTPase-Activating Proteins | 1 | 2019 | 73 | 0.050 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2019 | 54 | 0.050 |
Why?
|
| Perception | 2 | 2013 | 322 | 0.050 |
Why?
|
| Young Adult | 4 | 2018 | 10971 | 0.050 |
Why?
|
| Italy | 1 | 2018 | 90 | 0.050 |
Why?
|
| Maximal Voluntary Ventilation | 1 | 1998 | 9 | 0.050 |
Why?
|
| Physician-Patient Relations | 1 | 2003 | 528 | 0.050 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 158 | 0.050 |
Why?
|
| Lung Volume Measurements | 1 | 1998 | 42 | 0.050 |
Why?
|
| Proof of Concept Study | 1 | 2018 | 43 | 0.050 |
Why?
|
| Respiratory Muscles | 1 | 1998 | 32 | 0.050 |
Why?
|
| Veterans | 1 | 2007 | 906 | 0.050 |
Why?
|
| Systems Biology | 1 | 2018 | 61 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 526 | 0.040 |
Why?
|
| Models, Statistical | 2 | 2014 | 693 | 0.040 |
Why?
|
| Bone Diseases | 1 | 1998 | 52 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2017 | 56 | 0.040 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2002 | 407 | 0.040 |
Why?
|
| Bronchitis | 1 | 2017 | 48 | 0.040 |
Why?
|
| Harm Reduction | 1 | 2017 | 28 | 0.040 |
Why?
|
| Counseling | 1 | 2001 | 360 | 0.040 |
Why?
|
| Advance Directives | 1 | 1998 | 69 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 420 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2019 | 271 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2022 | 635 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2013 | 3307 | 0.040 |
Why?
|
| Cytokines | 1 | 2005 | 1981 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2017 | 69 | 0.040 |
Why?
|
| Body Temperature | 1 | 1998 | 281 | 0.040 |
Why?
|
| Postoperative Period | 2 | 2009 | 290 | 0.040 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2017 | 46 | 0.040 |
Why?
|
| Breathing Exercises | 2 | 1987 | 21 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 463 | 0.040 |
Why?
|
| Infant | 2 | 2021 | 8090 | 0.040 |
Why?
|
| Culture | 1 | 2017 | 136 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2016 | 63 | 0.040 |
Why?
|
| Siblings | 2 | 2008 | 277 | 0.040 |
Why?
|
| Symptom Flare Up | 1 | 2016 | 33 | 0.040 |
Why?
|
| Equipment Design | 1 | 1998 | 531 | 0.040 |
Why?
|
| Sarcoglycans | 1 | 2015 | 9 | 0.040 |
Why?
|
| Inflammation | 1 | 2007 | 2451 | 0.040 |
Why?
|
| Potassium Channels, Tandem Pore Domain | 1 | 2015 | 13 | 0.040 |
Why?
|
| Memory Disorders | 1 | 2017 | 183 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 434 | 0.040 |
Why?
|
| Mortality | 1 | 2018 | 328 | 0.040 |
Why?
|
| New Zealand | 1 | 2015 | 53 | 0.040 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2015 | 34 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 537 | 0.040 |
Why?
|
| Monitoring, Ambulatory | 2 | 2012 | 101 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2007 | 1755 | 0.040 |
Why?
|
| Pharmacogenomic Testing | 1 | 2015 | 51 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 602 | 0.040 |
Why?
|
| Reaction Time | 1 | 2017 | 487 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2015 | 76 | 0.040 |
Why?
|
| Diastole | 1 | 2015 | 173 | 0.040 |
Why?
|
| Tobacco Use Disorder | 1 | 2017 | 249 | 0.040 |
Why?
|
| Organizational Objectives | 1 | 2015 | 74 | 0.040 |
Why?
|
| CpG Islands | 1 | 2015 | 107 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 154 | 0.040 |
Why?
|
| Echocardiography, Doppler | 1 | 2015 | 128 | 0.040 |
Why?
|
| Patient Care Team | 2 | 1998 | 532 | 0.040 |
Why?
|
| Policy Making | 1 | 2015 | 90 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2017 | 1064 | 0.040 |
Why?
|
| Gastroesophageal Reflux | 1 | 2017 | 227 | 0.030 |
Why?
|
| Macrophages, Alveolar | 1 | 2018 | 371 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2005 | 2116 | 0.030 |
Why?
|
| Cadherins | 1 | 2015 | 191 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2015 | 209 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2009 | 1517 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2014 | 173 | 0.030 |
Why?
|
| Vaccination | 1 | 2022 | 962 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 1998 | 585 | 0.030 |
Why?
|
| Drug Repositioning | 1 | 2013 | 13 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2015 | 378 | 0.030 |
Why?
|
| Hypercholesterolemia | 1 | 2014 | 103 | 0.030 |
Why?
|
| Metered Dose Inhalers | 1 | 2013 | 25 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 2013 | 51 | 0.030 |
Why?
|
| Ventricular Function, Right | 1 | 2015 | 231 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 217 | 0.030 |
Why?
|
| Consensus | 1 | 2015 | 427 | 0.030 |
Why?
|
| Radiographic Image Enhancement | 1 | 2013 | 68 | 0.030 |
Why?
|
| Hypersensitivity | 2 | 2012 | 285 | 0.030 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2012 | 13 | 0.030 |
Why?
|
| Aortography | 1 | 2012 | 45 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2016 | 604 | 0.030 |
Why?
|
| Observation | 1 | 2012 | 58 | 0.030 |
Why?
|
| Scopolamine Derivatives | 1 | 2012 | 6 | 0.030 |
Why?
|
| Automation | 1 | 2012 | 75 | 0.030 |
Why?
|
| Immunoglobulin G | 2 | 2012 | 798 | 0.030 |
Why?
|
| Bronchospirometry | 1 | 2011 | 3 | 0.030 |
Why?
|
| Multidetector Computed Tomography | 1 | 2012 | 29 | 0.030 |
Why?
|
| Tiotropium Bromide | 1 | 2012 | 19 | 0.030 |
Why?
|
| Theophylline | 1 | 2012 | 65 | 0.030 |
Why?
|
| Ventricular Function, Left | 1 | 2015 | 489 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2011 | 84 | 0.030 |
Why?
|
| Depressive Disorder | 2 | 2010 | 386 | 0.030 |
Why?
|
| Blood Gas Analysis | 1 | 2011 | 88 | 0.030 |
Why?
|
| Nasopharynx | 1 | 2011 | 60 | 0.030 |
Why?
|
| Syndrome | 1 | 1992 | 347 | 0.030 |
Why?
|
| Telephone | 1 | 2012 | 163 | 0.030 |
Why?
|
| Patient Safety | 1 | 2014 | 309 | 0.030 |
Why?
|
| Observer Variation | 1 | 2012 | 335 | 0.030 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2012 | 143 | 0.030 |
Why?
|
| Macrolides | 1 | 2011 | 64 | 0.030 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2010 | 22 | 0.030 |
Why?
|
| Prednisone | 1 | 2012 | 246 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2015 | 781 | 0.030 |
Why?
|
| Forced Expiratory Flow Rates | 1 | 2010 | 17 | 0.030 |
Why?
|
| Protease Nexins | 1 | 2010 | 1 | 0.030 |
Why?
|
| Ku Autoantigen | 1 | 2010 | 14 | 0.030 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2011 | 153 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2011 | 395 | 0.030 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2011 | 118 | 0.030 |
Why?
|
| Mass Screening | 1 | 2018 | 1055 | 0.030 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2010 | 60 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2012 | 386 | 0.030 |
Why?
|
| Pulmonary Alveoli | 1 | 2013 | 407 | 0.030 |
Why?
|
| Intermittent Positive-Pressure Breathing | 2 | 1986 | 2 | 0.030 |
Why?
|
| Lipids | 1 | 2014 | 629 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 572 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 798 | 0.030 |
Why?
|
| Work of Breathing | 1 | 2009 | 4 | 0.030 |
Why?
|
| Respiratory Dead Space | 1 | 2009 | 6 | 0.030 |
Why?
|
| Heterozygote | 1 | 2010 | 270 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 2011 | 217 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 967 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2013 | 368 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 798 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2010 | 365 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2010 | 364 | 0.020 |
Why?
|
| Tidal Volume | 1 | 2009 | 82 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2009 | 148 | 0.020 |
Why?
|
| Varenicline | 1 | 2008 | 21 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 1640 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2010 | 572 | 0.020 |
Why?
|
| Fatigue | 1 | 2011 | 293 | 0.020 |
Why?
|
| Child | 3 | 2014 | 17711 | 0.020 |
Why?
|
| Workload | 1 | 2009 | 134 | 0.020 |
Why?
|
| Sleep | 1 | 2015 | 710 | 0.020 |
Why?
|
| Health Surveys | 1 | 2010 | 497 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2011 | 338 | 0.020 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2011 | 227 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2010 | 222 | 0.020 |
Why?
|
| Tracheostomy | 1 | 1989 | 94 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 402 | 0.020 |
Why?
|
| Random Allocation | 1 | 2008 | 402 | 0.020 |
Why?
|
| Mutation | 1 | 2018 | 3447 | 0.020 |
Why?
|
| Life Style | 1 | 2010 | 441 | 0.020 |
Why?
|
| Anxiety Disorders | 1 | 2010 | 290 | 0.020 |
Why?
|
| Mucus | 1 | 2007 | 55 | 0.020 |
Why?
|
| Internet | 1 | 2012 | 633 | 0.020 |
Why?
|
| Mouth Breathing | 1 | 1986 | 1 | 0.020 |
Why?
|
| Sleep Wake Disorders | 1 | 2011 | 295 | 0.020 |
Why?
|
| Hospital Bed Capacity, 300 to 499 | 1 | 1986 | 6 | 0.020 |
Why?
|
| Psychology | 1 | 2007 | 89 | 0.020 |
Why?
|
| Residual Volume | 1 | 2006 | 7 | 0.020 |
Why?
|
| Ventilation-Perfusion Ratio | 1 | 2006 | 16 | 0.020 |
Why?
|
| Diaphragm | 1 | 1986 | 45 | 0.020 |
Why?
|
| Latent TGF-beta Binding Proteins | 1 | 2006 | 5 | 0.020 |
Why?
|
| Immunity | 1 | 2007 | 125 | 0.020 |
Why?
|
| Pulmonary Surfactant-Associated Protein B | 1 | 2006 | 8 | 0.020 |
Why?
|
| Home Nursing | 1 | 1986 | 30 | 0.020 |
Why?
|
| Boston | 1 | 1986 | 69 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2007 | 242 | 0.020 |
Why?
|
| Ventilators, Mechanical | 1 | 1986 | 41 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 1421 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1986 | 226 | 0.020 |
Why?
|
| Family | 1 | 2010 | 579 | 0.020 |
Why?
|
| Aerosols | 1 | 1987 | 171 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 2629 | 0.020 |
Why?
|
| Body Weight | 1 | 2010 | 1020 | 0.020 |
Why?
|
| Arm | 1 | 1986 | 97 | 0.020 |
Why?
|
| Pressure | 1 | 1986 | 258 | 0.020 |
Why?
|
| Hypertension | 1 | 2014 | 1185 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2005 | 347 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2006 | 174 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2006 | 209 | 0.020 |
Why?
|
| Leg | 1 | 1986 | 240 | 0.020 |
Why?
|
| Health Behavior | 1 | 2010 | 716 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2009 | 863 | 0.020 |
Why?
|
| Patient Selection | 1 | 2008 | 694 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 368 | 0.020 |
Why?
|
| Fires | 1 | 2005 | 79 | 0.020 |
Why?
|
| Complement C4a | 1 | 2003 | 10 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2006 | 286 | 0.020 |
Why?
|
| Histamine | 1 | 2003 | 68 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2003 | 230 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 416 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2006 | 468 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2004 | 251 | 0.020 |
Why?
|
| Physical Therapy Modalities | 1 | 2005 | 283 | 0.020 |
Why?
|
| Air Pollutants | 1 | 2005 | 276 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2006 | 643 | 0.010 |
Why?
|
| Periodicals as Topic | 1 | 2004 | 264 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 1986 | 902 | 0.010 |
Why?
|
| Allergens | 1 | 2003 | 491 | 0.010 |
Why?
|
| Telemetry | 1 | 1998 | 48 | 0.010 |
Why?
|
| Hospital Charges | 1 | 1996 | 50 | 0.010 |
Why?
|
| Tracheotomy | 1 | 1986 | 22 | 0.010 |
Why?
|
| Humidity | 1 | 1986 | 40 | 0.010 |
Why?
|
| Inhalation | 1 | 1986 | 30 | 0.010 |
Why?
|
| Apnea | 1 | 1986 | 24 | 0.000 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 1986 | 58 | 0.000 |
Why?
|
| Muscular Diseases | 1 | 1986 | 103 | 0.000 |
Why?
|
| Monitoring, Physiologic | 1 | 1986 | 277 | 0.000 |
Why?
|